PMID- 27900004
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 12
IP  - 5
DP  - 2016 Nov
TI  - Role of specific DNA mutations in the peripheral blood of colorectal cancer 
      patients for the assessment of tumor stage and residual disease following tumor 
      resection.
PG  - 3356-3362
AB  - In the present study, the detection of tumor-specific KRAS proto-oncogene, GTPase 
      (KRAS) and B-Raf proto-oncogene, serine/threonine kinase (BRAF) mutations in the 
      peripheral blood of colorectal cancer (CRC) patients at all stages and adenomas 
      was used for the estimation of disease stage prior to surgery and for residual 
      disease following surgery. A total of 65 CRC patients were enrolled. The primary 
      tumor tested positive for the specific mutations (KRAS mutations in codons 12, 
      13, 61, 117 or 146 and BRAF mutations in codon 600) in 35 patients. In all these 
      patients, the specimen of normal bowel resected with the tumor was also tested 
      for the presence of the same mutations in order to exclude the germ-line 
      mutations. Only patients who tested positive for the specific mutation in the 
      primary tumor were included in further analysis for the presence of 
      tumor-specific mutation in the peripheral blood. No statistically significant 
      differences were found between the detection rates of tumor mutations in the 
      blood and different tumor stages (P=0.491). However, statistically significant 
      differences in the proportions of patients with detected tumor-specific DNA 
      mutations in the peripheral blood were found when comparing the groups of 
      patients with R0 and R2 resections (P=0.038). Tumor-specific DNA mutations in the 
      peripheral blood were more frequently detected in the patients with an incomplete 
      surgical clearance of the tumor due to macroscopic residual disease (R2 
      resections). Therefore, the study concludes that the follow-up of somatic KRAS- 
      and BRAF-mutated DNA in the peripheral blood of CRC patients may be useful in 
      assessing the surgical clearance of the disease.
FAU - Norcic, Gregor
AU  - Norcic G
AD  - Clinical Department of Abdominal Surgery, University Medical Centre Ljubljana, 
      1000 Ljubljana, Slovenia.
FAU - Jelenc, Franc
AU  - Jelenc F
AD  - Clinical Department of Abdominal Surgery, University Medical Centre Ljubljana, 
      1000 Ljubljana, Slovenia.
FAU - Cerkovnik, Petra
AU  - Cerkovnik P
AD  - Department of Molecular Diagnostics, Institute of Oncology Ljubljana, 1000 
      Ljubljana, Slovenia.
FAU - Stegel, Vida
AU  - Stegel V
AD  - Department of Molecular Diagnostics, Institute of Oncology Ljubljana, 1000 
      Ljubljana, Slovenia.
FAU - Novakovic, Srdjan
AU  - Novakovic S
AD  - Department of Molecular Diagnostics, Institute of Oncology Ljubljana, 1000 
      Ljubljana, Slovenia.
LA  - eng
PT  - Journal Article
DEP - 20160901
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC5103950
OTO - NOTNLM
OT  - BRAF
OT  - CK20
OT  - KRAS
OT  - colorectal cancer
OT  - peripheral blood
OT  - residual disease
OT  - staging
EDAT- 2016/12/03 06:00
MHDA- 2016/12/03 06:01
PMCR- 2016/09/01
CRDT- 2016/12/01 06:00
PHST- 2015/04/22 00:00 [received]
PHST- 2016/08/12 00:00 [accepted]
PHST- 2016/12/01 06:00 [entrez]
PHST- 2016/12/03 06:00 [pubmed]
PHST- 2016/12/03 06:01 [medline]
PHST- 2016/09/01 00:00 [pmc-release]
AID - OL-0-0-5078 [pii]
AID - 10.3892/ol.2016.5078 [doi]
PST - ppublish
SO  - Oncol Lett. 2016 Nov;12(5):3356-3362. doi: 10.3892/ol.2016.5078. Epub 2016 Sep 1.